Partner Therapeutics Announces Publication of a Retrospective Cohort Review of 15 LEUKINE® Treated Patients with Pediatric Malignancies and Invasive Fungal Disease Refractory to Antifungal TherapyDec 15, 2022
BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patientsSep 20, 2021
Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE)Apr 29, 2021
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's DiseaseMar 24, 2021
Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down Syndrome and Normal AgingMar 29, 2022
“A Drug Before Its Time?” LEUKINE® systematic review highlights innate and adaptive immune activity that may improve cancer outcomes and reduce toxicityAug 17, 2021
Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson’s DiseaseMay 19, 2021
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s DiseaseMar 24, 2021